pharma · Breast Cancer · NSCLC, synchronous oligo-metastatic
Impact Therapeutics
Partner Therapeutics Limited
Impact Therapeutics clinical programs — 7 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 1004, 10th Floor, Lodha Supremus Saki Vihar Road, Powai, Mumbai-400072, Maharashtra 400072, IN, Lexington
- Founded
- 2010
- Employees
- 8
- Programs
- 12
- Drugs
- 26
- Patents
- 0
Impact Therapeutics projects
7 ClinicalTrials.gov programs sponsored by Impact Therapeutics.
Impact Therapeutics has 7 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
67-22 PREcoopERA
Partner Therapeutics Limited
ER-positive/HER2-negative early breast cancer
1 trial -
Adagrasib
Partner Therapeutics Limited
Patients with KRASG12C-mutant NSCLC, including patients aged ≥18 years with poor performance status (ECOG PS=2) Cohort 1 or elderly (≥70 years) (ECOG PS=0-1) Cohort 2
1 trial -
ETOP 14-18 CHESS
Partner Therapeutics Limited
NSCLC, synchronous oligo-metastatic
1 trial -
ETOP 23-22 RAISE
Partner Therapeutics Limited
Extensive-disease small cell lung cancer and high SLFN11-expression
1 trial -
JNJ-73841937 for Patients with EGFR-mutant (L858…
Partner Therapeutics Limited
Patients with EGFR-mutant (L858R or del19 only) advanced non-squamous NSCLC, who have progressed on previous treatment with a third-generation EGFR-TKI.
1 trial -
MCLA-128
Partner Therapeutics Limited
Solid Tumors
1 trial -
Tarlatamab, Tarlatamab
Partner Therapeutics Limited
Patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2
1 trial
Frequently asked questions
How many clinical projects does Impact Therapeutics have?
7 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.